Buy Live Nation (LYV) Immediately
Wall Street legend who helped create America’s stock-rating system says this stock could soon be rated a “Strong Buy” at every bank in New York City and Boston. “It’s all part of the biggest prediction of my 50-year career on Wall Street,” he says. “A massive and surprising new transition that could determine the next group of millionaires.”
Click here to learn more.

ONC Insider Trading (Oncolytics Biotech)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$25,123.70
Insider Selling (Last 12 Months): C$0.00

Oncolytics Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at Oncolytics Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Oncolytics Biotech Share Price & Price History

Current Price: C$2.44
Price Change: Price Increase of +0.16 (7.02%)
As of 01/25/2022 01:00 AM ET

This chart shows the closing price history over time for ONC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
A Breakthrough Technology in Cyber Security is Here
The $150B cyber security market is about to get a major shakeup by this emerging player.
Continue Reading

Oncolytics Biotech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/7/2021Angela Frances HolthamDirectorBuy7,000C$3.59C$25,123.70108,336
8/28/2020Angela Frances HolthamDirectorBuy4,300C$2.35C$10,105.0076,518
3/27/2020Angela Frances HolthamDirectorBuy3,000C$2.03C$6,090.003,000
10/2/2019Matthew CoffeyDirectorBuy10,000C$0.56C$5,636.4047,923
8/16/2019Bernd Robert SeizingerDirectorBuy25,000C$0.80C$19,965.0038,828
6/18/2019Kirk LookSenior OfficerBuy1,500C$2.25C$3,370.5010,923
6/18/2019Matthew CoffeyDirectorBuy1,300C$2.27C$2,951.0037,923
See Full Table
Insider Trading at Oncolytics Biotech?
Sign-up to receive's daily insider buying and selling report for Oncolytics Biotech and related companies.

SEC Filings (Institutional Ownership Changes) for Oncolytics Biotech (TSE:ONC)

Oncolytics Biotech logo
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Read More on Oncolytics Biotech

Today's Range

Now: C$2.44
Low: C$2.20
High: C$2.50

50 Day Range

MA: C$2.03
Low: C$1.65
High: C$2.47

52 Week Range

Now: C$2.44
Low: C$1.59
High: C$6.06


184,935 shs

Average Volume

176,117 shs

Market Capitalization

C$134.27 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Oncolytics Biotech?

Oncolytics Biotech's top insider shareholders include:
  1. Angela Frances Holtham (Director)
Bezos, Elon Musk and Zuckerberg Betting Big on S.C.G.
The "Black Box" Device Bringing the Age of the Smartphone to an End.
Learn More